This biotech company develops small-molecule therapeutics to combat antimicrobial-resistant bacterial infections. Their lead compounds specifically disrupt swarming behavior in *Pseudomonas aeruginosa*, aiming to prevent infections and enhance the efficacy of existing antibiotics.
Funding
Funding not disclosed
Founders
Product
Problem
Antimicrobial resistance is rising, making bacterial infections increasingly difficult to treat. *Pseudomonas aeruginosa*, a priority pathogen, causes severe hospital-acquired infections and exhibits high levels of resistance, creating a need for novel treatment approaches.
Solution
Veirulence Ltd. develops small-molecule therapeutics that target virulence factors in bacteria, specifically disrupting swarming behavior in *P. aeruginosa*. By inhibiting flagella expression and function, the therapeutics prevent bacteria from establishing infections. This approach not only acts as a prophylactic treatment for high-risk patients but also enhances the efficacy of existing antibiotics in acute infections, offering an antibiotic-sparing and antibiotic-enhancing treatment option. The molecules allow the body's immune system to more effectively clear infections and reduce antimicrobial resistance.
Target Audience
The primary target audience includes clinicians treating patients at high risk of *P. aeruginosa* infections, such as those with burns, and those managing acute infections caused by this pathogen.
Features
- Proprietary small molecules inhibit bacterial flagella expression and function.
- Disrupts swarming, adhesion, and invasion, preventing infection establishment.
- Synergistic effect with antibiotics enhances their efficacy.
- Potential as a prophylactic monotherapy in high-risk patients colonized with *P. aeruginosa*.
- Can be used in combination treatment for patients with acute *P. aeruginosa* infections.